DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

Kemas kini terakhir: 06 Jan, 4:38PM

69.89

2.24 (3.31%)

  • 1H 3.31%
  • 5H -5.55%
  • 1B 0.00%
  • 6B -8.52%
  • Tahun Ke Tarikh 5.03%
  • 1T -20.87%
  • 5T -30.68%
Penutupan Terdahulu 67.65
Buka 67.65
Jumlah Dagangan 3,966,079
Purata Dagangan (3B) 5,795,374
Modal Pasaran 27,407,730,688
Harga / Pendapatan (P/E TTM) 38.83
Harga / Pendapatan (P/E Ke hadapan) 28.57
Harga / Jualan (P/S) 6.39
Harga / Buku (P/B) 10.13
Julat 52 Minggu
54.11 (-22%) — 93.25 (33%)
Tarikh Pendapatan 30 Oct 2025
Margin Keuntungan 12.90%
Margin Operasi (TTM) 12.91%
EPS Cair (TTM) 1.33
Pertumbuhan Hasil Suku Tahunan (YOY) 12.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -28.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 113.97%
Nisbah Semasa (MRQ) 1.50
Aliran Tunai Operasi (OCF TTM) 964.10 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 509.04 M
Pulangan Atas Aset (ROA TTM) 5.97%
Pulangan Atas Ekuiti (ROE TTM) 23.72%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Devices (US) Bercampur Bercampur
Medical Devices (Global) Bercampur Bercampur
Stok DexCom, Inc. Menurun Menurun

AISkor Stockmoo

-0.3
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam 3.0
Volatiliti Harga -2.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal 0.5
Purata -0.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
DXCM 27 B - 38.83 10.13
PODD 21 B - 86.12 13.04
SSII 1 B - - 20.66
IRTC 6 B - - 42.64
TMDX 5 B - 55.88 13.56
ESTA 2 B - - 122.85

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Sektor Healthcare
Industri Medical Devices
Gaya Pelaburan Mid Growth
% Dimiliki oleh Orang Dalam 0.42%
% Dimiliki oleh Institusi 97.10%
Julat 52 Minggu
54.11 (-22%) — 93.25 (33%)
Julat Harga Sasaran
68.00 (-2%) — 90.00 (28%)
Tinggi 90.00 (Argus Research, 28.77%) Beli
Median 77.00 (10.17%)
Rendah 68.00 (Evercore ISI Group, -2.70%) Pegang
Purata 77.86 (11.40%)
Jumlah 5 Beli, 1 Pegang, 1 Jual
Harga Purata @ Panggilan 64.89
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 12 Jan 2026 71.00 (1.59%) Jual 70.98
Bernstein 09 Jan 2026 86.00 (23.05%) Beli 67.40
Mizuho 17 Dec 2025 78.00 (11.60%) Beli 65.75
Citigroup 11 Dec 2025 77.00 (10.17%) Beli 68.94
Morgan Stanley 02 Dec 2025 75.00 (7.31%) Beli 64.45
10 Nov 2025 63.00 (-9.86%) Pegang 54.84
Evercore ISI Group 25 Nov 2025 68.00 (-2.70%) Pegang 61.69
Argus Research 07 Nov 2025 90.00 (28.77%) Beli 55.00
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
BROWN MICHAEL JON 74.00 74.00 4,470 330,780
LEACH JACOB STEVEN 74.00 74.00 5,252 388,648
SAYER KEVIN R 74.00 74.00 36,961 2,735,114
STERN SADIE 74.00 74.00 4,467 330,558
SYLVAIN JEREME M 74.00 74.00 4,471 330,854
Jumlah Keseluruhan Kuantiti Bersih 55,621
Jumlah Keseluruhan Nilai Bersih ($) 4,115,954
Purata Pembelian Keseluruhan ($) 74.00
Purata Jualan Keseluruhan ($) 74.00
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
SAYER KEVIN R Pegawai 29 Jan 2026 Diperolehi (+) 71,218 74.00 5,270,132
SAYER KEVIN R Pegawai 29 Jan 2026 Dibuang (-) 34,257 74.00 2,535,018
SYLVAIN JEREME M Pegawai 29 Jan 2026 Diperolehi (+) 7,123 74.00 527,102
SYLVAIN JEREME M Pegawai 29 Jan 2026 Dibuang (-) 2,652 74.00 196,248
BROWN MICHAEL JON Pegawai 29 Jan 2026 Diperolehi (+) 7,123 74.00 527,102
BROWN MICHAEL JON Pegawai 29 Jan 2026 Dibuang (-) 2,653 74.00 196,322
STERN SADIE Pegawai 29 Jan 2026 Diperolehi (+) 7,123 74.00 527,102
STERN SADIE Pegawai 29 Jan 2026 Dibuang (-) 2,656 74.00 196,544
LEACH JACOB STEVEN Pegawai 29 Jan 2026 Diperolehi (+) 8,310 74.00 614,940
LEACH JACOB STEVEN Pegawai 29 Jan 2026 Dibuang (-) 3,058 74.00 226,292
  • 3M
Tarikh Jenis Butiran
04 Feb 2026 Pengumuman Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
27 Jan 2026 Pengumuman Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
12 Jan 2026 Pengumuman Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
07 Jan 2026 Pengumuman Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer
26 Dec 2025 Pengumuman Latest SueWallSt Podcast: What DXCM Investors Need to Know About the Lawsuit
23 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
22 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
19 Dec 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
17 Dec 2025 Pengumuman Latest SueWallSt Podcast: What DXCM Investors Need to Know About the Lawsuit
16 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
15 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
15 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
12 Dec 2025 Pengumuman SueWallSt Podcast Explains Class Action Against DexCom, Inc. (DXCM)
11 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
09 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
08 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
08 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
05 Dec 2025 Pengumuman SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations
05 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Pengumuman Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
04 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Dec 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
02 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
02 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
01 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
01 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
25 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
25 Nov 2025 Pengumuman GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
24 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
20 Nov 2025 Pengumuman Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
19 Nov 2025 Pengumuman Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
18 Nov 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
17 Nov 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
14 Nov 2025 Pengumuman Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
06 Nov 2025 Pengumuman Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
06 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda